Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
glioblastoma
heterogeneity
methylation
phylogeny
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
18
03
2022
revised:
01
07
2022
accepted:
17
07
2022
pubmed:
3
9
2022
medline:
25
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Intratumoral heterogeneity at the cellular and molecular level is a hallmark of glioblastoma (GB) that contributes to treatment resistance and poor clinical outcome. Little is known regarding epigenetic heterogeneity and intratumoral phylogeny and their implication for molecular classification and targeted therapies. Multiple tissue biopsies (238 in total) were sampled from 56 newly-diagnosed, treatment-naive GB patients from a prospective in-house cohort and publicly available data and profiled for DNA methylation using the Illumina MethylationEPIC array. Methylation-based classification using the glioma classifier developed by Ceccarelli et al. and estimation of the MGMT promoter methylation status via the MGMT-STP27 model were carried out. In addition, copy number variations (CNVs) and phylogeny were analyzed. Almost half of the patients (22/56, 39%) harbored tumors composed of heterogeneous methylation subtypes. We found two predominant subtype combinations: classic-/mesenchymal-like, and mesenchymal-/pilocytic astrocytoma-like. Nine patients (16%) had tumors composed of subvolumes with and without MGMT promoter methylation, whereas 20 patients (36%) were homogeneously methylated, and 27 patients (48%) were homogeneously unmethylated. CNV analysis revealed high variations in many genes, including CDKN2A/B, EGFR, and PTEN. Phylogenetic analysis correspondingly showed a general pattern of CDKN2A/B loss and gain of EGFR, PDGFRA, and CDK4 during early stages of tumor development. (Epi)genetic intratumoral heterogeneity is a hallmark of GB, both at DNA methylation and CNV level. This intratumoral heterogeneity is of utmost importance for molecular classification as well as for defining therapeutic targets in this disease, as single biopsies might underestimate the true molecular diversity in a tumor.
Sections du résumé
BACKGROUND
Intratumoral heterogeneity at the cellular and molecular level is a hallmark of glioblastoma (GB) that contributes to treatment resistance and poor clinical outcome. Little is known regarding epigenetic heterogeneity and intratumoral phylogeny and their implication for molecular classification and targeted therapies.
PATIENTS AND METHODS
Multiple tissue biopsies (238 in total) were sampled from 56 newly-diagnosed, treatment-naive GB patients from a prospective in-house cohort and publicly available data and profiled for DNA methylation using the Illumina MethylationEPIC array. Methylation-based classification using the glioma classifier developed by Ceccarelli et al. and estimation of the MGMT promoter methylation status via the MGMT-STP27 model were carried out. In addition, copy number variations (CNVs) and phylogeny were analyzed.
RESULTS
Almost half of the patients (22/56, 39%) harbored tumors composed of heterogeneous methylation subtypes. We found two predominant subtype combinations: classic-/mesenchymal-like, and mesenchymal-/pilocytic astrocytoma-like. Nine patients (16%) had tumors composed of subvolumes with and without MGMT promoter methylation, whereas 20 patients (36%) were homogeneously methylated, and 27 patients (48%) were homogeneously unmethylated. CNV analysis revealed high variations in many genes, including CDKN2A/B, EGFR, and PTEN. Phylogenetic analysis correspondingly showed a general pattern of CDKN2A/B loss and gain of EGFR, PDGFRA, and CDK4 during early stages of tumor development.
CONCLUSIONS
(Epi)genetic intratumoral heterogeneity is a hallmark of GB, both at DNA methylation and CNV level. This intratumoral heterogeneity is of utmost importance for molecular classification as well as for defining therapeutic targets in this disease, as single biopsies might underestimate the true molecular diversity in a tumor.
Identifiants
pubmed: 36055049
pii: S2059-7029(22)00194-6
doi: 10.1016/j.esmoop.2022.100566
pmc: PMC9588899
pii:
doi:
Substances chimiques
DNA Modification Methylases
EC 2.1.1.-
DNA Repair Enzymes
EC 6.5.1.-
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100566Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have declared no conflicts of interests.
Références
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33066251
Neuro Oncol. 2021 Dec 1;23(12):2054-2065
pubmed: 34049406
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Genome Biol. 2012 Jun 15;13(6):R44
pubmed: 22703947
Sci Rep. 2016 Mar 04;6:22477
pubmed: 26940435
Acta Neuropathol. 2018 Aug;136(2):181-210
pubmed: 29967940
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Acta Neuropathol. 2012 Oct;124(4):547-60
pubmed: 22810491
Acta Neuropathol. 2014 Oct;128(4):561-71
pubmed: 25008768
Neuro Oncol. 2019 May 6;21(5):616-627
pubmed: 30668814
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Nature. 2017 Sep 14;549(7671):227-232
pubmed: 28854171
Genomics. 2014 Nov;104(5):347-51
pubmed: 25205306
J Clin Oncol. 2015 Sep 1;33(25):2735-44
pubmed: 26124478
Genes Dis. 2018 Feb 21;5(1):43-45
pubmed: 30258934
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
CA Cancer J Clin. 2021 Sep;71(5):381-406
pubmed: 34427324
Sci Rep. 2015 Nov 05;5:16238
pubmed: 26538165
Acta Neuropathol. 2018 Jul;136(1):153-166
pubmed: 29687258
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Front Oncol. 2019 Sep 26;9:963
pubmed: 31616641
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Genome Biol. 2010;11(7):R76
pubmed: 20649963
Neurooncol Adv. 2021 Jan 23;2(Suppl 4):iv35-iv41
pubmed: 33521639
Epigenomics. 2011 Dec;3(6):771-84
pubmed: 22126295
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Nat Genet. 2017 Apr;49(4):594-599
pubmed: 28263318
BMC Bioinformatics. 2019 Aug 16;20(1):428
pubmed: 31419933
Nat Commun. 2021 Jul 22;12(1):4472
pubmed: 34294691